Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade

Description of Dilpacimab Biosimilar - Anti-DLL4, VEGFA mAb - Research Grade

Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade Introduction

Dilpacimab Biosimilar is a monoclonal antibody that targets both Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGFA). It is a research grade antibody that has shown promising results in pre-clinical studies and is currently being evaluated for its potential therapeutic applications.

Structure

Dilpacimab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to its target molecules, while the constant region determines its effector functions.

The antibody has a molecular weight of approximately 150 kDa and a half-life of 21 days. It is stable at room temperature and can be stored for long periods without losing its activity.

Activity

Dilpacimab Biosimilar specifically targets both DLL4 and VEGFA, two important proteins involved in angiogenesis, the process of forming new blood vessels. DLL4 is a ligand for the Notch signaling pathway, which plays a crucial role in regulating cell differentiation and proliferation. VEGFA is a key growth factor that promotes the growth and survival of new blood vessels.

By targeting both DLL4 and VEGFA, Dilpacimab Biosimilar inhibits the formation of new blood vessels, which is essential for the growth and spread of tumors. This makes it a potential therapeutic agent for cancer treatment, especially in solid tumors.

In addition, Dilpacimab Biosimilar has been shown to have anti-inflammatory properties by blocking the activation of immune cells and reducing the production of pro-inflammatory cytokines. This makes it a promising candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis.

Application

Dilpacimab Biosimilar is currently being evaluated in pre-clinical studies for its potential therapeutic applications. It has shown promising results in inhibiting tumor growth and reducing inflammation in animal models. It is also being investigated for its potential use in combination with other anti- cancer therapies to enhance their effectiveness.

In addition, Dilpacimab Biosimilar has the potential to be used as a diagnostic tool for detecting DLL4 and VEGFA expression in tumors. This can help in identifying patients who are likely to benefit from the antibody treatment.

Conclusion

Dilpacimab Biosimilar is a research grade monoclonal antibody that targets both DLL4 and VEGFA. Its dual mechanism of action makes it a promising candidate for the treatment of cancer and inflammatory diseases. Further studies are needed to fully understand its potential and to determine its safety and efficacy in human clinical trials.

Keywords

antibody, therapeutic target, Dilpacimab Biosimilar, Anti-DLL4, VEGFA mAb, research grade, structure, activity, application

Dilpacimab Biosimilar - Anti-DLL4, VEGFA mAb binds to VEGFA / VEGF165, C-His, recombinant protein in indirect ELISA Assay

Immobilized VEGFA / VEGF165, C-His, recombinant protein (cat. No.PX-P5977) at 0.5µg/mL (100µL/well) can bind to Dilpacimab Biosimilar - Anti-DLL4, VEGFA mAb (cat. No.PX-TA1525) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450